<DOC>
	<DOCNO>NCT00244829</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . Giving imatinib mesylate donor stem cell transplant may prevent recurrence Philadelphia chromosome-positive leukemia . PURPOSE : This phase I/II trial study side effect give imatinib mesylate donor stem cell transplant see well work treat patient Philadelphia chromosome-positive leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate After Donor Stem Cell Transplant Treating Patients With Philadelphia Chromosome-Positive Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety adjuvant imatinib mesylate allogeneic hematopoietic stem cell transplantation ( AHSCT ) patient high-risk Philadelphia chromosome-positive leukemia . Secondary - Determine bcr/abl transcript load first 90 day AHSCT patient treat drug time engraftment . - Determine 1-year survival patient treated drug . OUTLINE : This open-label , pilot , multicenter study . Beginning within 14-30 day allogeneic stem cell transplantation , patient receive oral imatinib mesylate daily 1 year transplantation . Treatment continue absence unacceptable toxicity disease progression . Patients follow survival . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute lymphoblastic leukemia chronic myeloid leukemia ( CML ) characterize p^190 and/or p^210 bcr/abl gene rearrangement Accelerated blastic phase CML CML second great chronic phase No imatinib mesylateresistant leukemia Planned allogeneic hematopoietic stem cell transplantation Availability appropriately match related unrelated donor Autologous nonmyeloablative transplantation allow None follow within 4 day date neutrophil engraftment* : More 5 % marrow blast Circulating peripheral blood leukemic blast Aberrant antigen expression marrow myeloblasts ≥ 1 % multidimensional flow cytometric assay Presence bcr/abl &gt; 5 % marrow interphase nuclei fluorescent situ hybridization More 1 20 Philadelphia chromosomepositive marrow metaphase CNS involvement leukemia NOTE : *The date neutrophil engraftment define second consecutive day peripheral blood absolute neutrophil count exceed 500/mm3 PATIENT CHARACTERISTICS : Performance status Not specify Life expectancy At least 2 month Hematopoietic See Disease Characteristics Absolute neutrophil count ≥ 1,200/mm^3 ( use filgrastim [ GCSF ] allow ) Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known imatinib mesylate hypersensitivity No disease severely limit life expectancy PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
</DOC>